Interviews

Jonathan C. Trent, MD, PhD, discusses why it is necessary for patients with gastrointestinal stromal tumors to have comprehensive testing to find actionable genomic alterations.

The results of a phase 1b trial looking at the use of acalabrutinib for patients with treatment-naive or relapsed/refractory mantle cell lymphoma has provided the support needed for the phase 3 ECHO study of this treatment.

Cyrus M. Khan, MD, discusses the issues with PI3K inhibitor trials in patients with chronic lymphocytic leukemia and the potential role of these drugs.

In an interview with Targeted Oncology, Daniel P. Petrylak, MD, discussed findings from the TROPHY-U-01 study for patients with mUC, and what the next steps for research are.

A review of fam-trastuzumab deruxtecan nxki shows how it has become a standard of care for patients with metastatic breast cancer that is HER2-positive.

In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the implications of findings from the phase 1 study assessing olaparib and high-dose chemotherapy in patients with relapsed/refractory lymphomas.

In an interview, Shilpa Gupta, MD, discussed findings from cohort A of Study EV-103 in patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma.

Barbara Buttin, MD, discusses the PAOLA-1 clinical trial and it impact on the first-line treatment of ovarian cancer.

Ruchi Garg, MD, discusses several important ongoing studies of targeted therapies in patients with recurrent endometrial cancer.

Michael T. Tees, MD, discusses the data behind ALLO-501A, an allogeneic chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma.

Eric A. Singer, MD, MS, discusses which patients he believes would benefit most from adjuvant therapy for high-risk renal cell carcinoma.

Yi Lin MD, PhD explains how results from CARTITUDE-1 impact the treatment landscape for relapsed or refractory multiple myeloma.

In an interview with Targeted Oncology, Hans C. Lee, MD, discussed the safety and efficacy results of the phase 2 LINKER-MM1 study.

John Diaz, discusses key targets for cervical cancer and ovarian cancer.

Federico Albrecht, MD, comments on clinical trials supporting the use of PD-L1 inhibitor therapy in combination with standard chemotherapy for the treatment of patients with extensive-stage small cell lung cancer.

Andreas Varkaris, MD, PhD, discusses PIK3CA mutations in breast cancer and the novel therapies being developed to treat these tumors.

Andrew J. Armstrong, MD, ScM, discusses the methods behind a study that established a digital pathology biomarker for the benefit of androgen deprivation therapy in localized high-risk prostate cancer.

Aaron T. Gerds, MD, MS, discusses the 48-week results of the MOMENTUM trial and where momelotinib goes from here in the treatment of patients with myelofibrosis.

Alicia K. Morgans, MD, MPH, discusses real-world evidence the shows patients with non-metastatic castration resistant prostate cancer on darolutamide have a longer time till discontinuation when compared with enzalutamide and apalutamide.

In an interview with Targeted Oncology, Hun Ju Lee, MD, discussed the encouraging responses shown with the combination of zilovertamab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia, and highlighted other studies making headway in the field.

Nicholas J. Robert, MD, discusses a study of the social determinants of a patient’s health related to the use of genomic testing in women with breast cancer.

Frederick Locke, MD, reviews the current landscape of approved CAR T-cell therapies for patients with large B-cell lymphoma and how off the shelf options like ALLO-501 and ALLO-501A can fill the gap for patients waiting for treatment.

Barbara Buttin, MD, provided insight on the phase 3 DUO-O trial and what it implies for the future of ovarian cancer treatment.

In an interview with Targeted Oncology, Barbara Buttin, MD, discussed important ovarian cancer research for which results were presented during the 2023 ASCO Annual Meeting.

Ben Derman, MD, discusses next steps for using minimal residual disease-guided discontinuation of maintenance therapy in patients with multiple myeloma.

Matthew Powell, MD, discusses findings from the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial of dostarlimab in combination with chemotherapy for patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer.

In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed real-world findings from a trial evaluating second-line maintenance niraparib in patients with recurrent ovarian cancer.

In an interview with Targeted Oncology, Antonio Ucar, MD, discussed the evolving role of sunitinib for the second-line treatment of gastrointestinal stromal tumors, and the Peak study.

In an interview with Targeted Oncology, David Peereboom, MD, discusses the correlation of immune activity to durable responses with VT1021 in patients with recurrent glioblastoma.

In an interview with Targeted Oncology, Mitul Gandhi, MD, reviewed the latest guideline recommendations for the workup and treatment of acute myeloid leukemia.